Correlation Between Abcellera Biologics and Stratasys

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Abcellera Biologics and Stratasys at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Abcellera Biologics and Stratasys into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Abcellera Biologics and Stratasys, you can compare the effects of market volatilities on Abcellera Biologics and Stratasys and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Abcellera Biologics with a short position of Stratasys. Check out your portfolio center. Please also check ongoing floating volatility patterns of Abcellera Biologics and Stratasys.

Diversification Opportunities for Abcellera Biologics and Stratasys

0.36
  Correlation Coefficient

Weak diversification

The 3 months correlation between Abcellera and Stratasys is 0.36. Overlapping area represents the amount of risk that can be diversified away by holding Abcellera Biologics and Stratasys in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Stratasys and Abcellera Biologics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Abcellera Biologics are associated (or correlated) with Stratasys. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Stratasys has no effect on the direction of Abcellera Biologics i.e., Abcellera Biologics and Stratasys go up and down completely randomly.

Pair Corralation between Abcellera Biologics and Stratasys

Given the investment horizon of 90 days Abcellera Biologics is expected to under-perform the Stratasys. In addition to that, Abcellera Biologics is 1.06 times more volatile than Stratasys. It trades about -0.04 of its total potential returns per unit of risk. Stratasys is currently generating about 0.0 per unit of volatility. If you would invest  1,401  in Stratasys on November 28, 2024 and sell it today you would lose (327.00) from holding Stratasys or give up 23.34% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Abcellera Biologics  vs.  Stratasys

 Performance 
       Timeline  
Abcellera Biologics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Abcellera Biologics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite quite persistent fundamental indicators, Abcellera Biologics is not utilizing all of its potentials. The current stock price mess, may contribute to short-term losses for the institutional investors.
Stratasys 

Risk-Adjusted Performance

Insignificant

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Stratasys are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unfluctuating basic indicators, Stratasys unveiled solid returns over the last few months and may actually be approaching a breakup point.

Abcellera Biologics and Stratasys Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Abcellera Biologics and Stratasys

The main advantage of trading using opposite Abcellera Biologics and Stratasys positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Abcellera Biologics position performs unexpectedly, Stratasys can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Stratasys will offset losses from the drop in Stratasys' long position.
The idea behind Abcellera Biologics and Stratasys pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.

Other Complementary Tools

Global Correlations
Find global opportunities by holding instruments from different markets
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.